Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Fenofibrate and Propranolol in Burn Patients
NCT02452255 · The University of Texas Medical Branch, Galveston · PHASE2/PHASE3 · terminated · last registry update 2019-11-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Shriner's Burn Hospital closed the study and access to study-related data is unavailable. We are unable to submit the additional information or results-data” | – | Registry record, The University of Texas Medical Branch, Galveston |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-19Phase 3 first posted: Polaryx Therapeutics, Inc., PLX-200 + Placebo (NCT04637282)
- 2020-09-23Phase 3 first posted: Hôpital Necker-Enfants Malades, Béfizal (NCT04561466)
- 2020-09-16Results posted on the registry: Jaeb Center for Health Research, Pemafibrate + Placebo (NCT03345901)
- 2020-09-16Also stopped (terminated): Jaeb Center for Health Research, Pemafibrate + Placebo (NCT03345901)
- 2020-08-31Also stopped (terminated): Genfit, elafibranor 120mg + Placebo (NCT03953456)
- 2020-08-26Phase 3 first posted: Ipsen, Elafibranor 80mg + Placebo (NCT04526665)
- 2020-03-24Results posted on the registry: Asahi Kasei Therapeutics, Inc., LCP-AtorFen (NCT00664859)
- 2020-03-16Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy + Placebo of Bezafibrate in addition to standard UDCA therapy (NCT04309773)
- 2020-02-05Results posted on the registry: Asahi Kasei Therapeutics, Inc., LCP-AtorFen + atorvastatin (NCT00504829)
- 2019-12-11Phase 3 first posted: Asian Institute of Gastroenterology, India, Saroglitazar + Vitamin E (NCT04193982)
- 2019-11-29Also stopped (terminated): The University of Texas Medical Branch, Galveston, Fenofibrate + Sugar Pill (NCT01574131)
- 2019-09-24Results posted on the registry: Genfit, Elafibranor 80 mg + Elafibranor 120 mg (NCT03124108)
- 2019-09-09Results posted on the registry: Sanofi, Alirocumab SAR236553 + Atorvastatin (NCT02984982)
- 2019-09-06Results posted on the registry: Sanofi, alirocumab SAR236553 (REGN727) + statins (NCT02890992)
- 2019-06-26Results posted on the registry: VA Office of Research and Development, Fenofibrate (NCT02455336)
- 2019-03-11Phase 3 first posted: Singapore General Hospital, Fenofibrate (NCT03869931)
- 2019-03-08Results posted on the registry: Eli Lilly and Company, LY2409021 + Gemfibrozil (NCT01836198)
- 2019-02-26Results posted on the registry: Washington University School of Medicine, Fenofibrate + Placebo for fenofibrate (NCT01752842)
- 2019-02-01Results posted on the registry: University of Texas Southwestern Medical Center, Gemfibrozil (NCT02638597)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision